vs
Side-by-side financial comparison of James River Group Holdings, Inc. (JRVR) and Pacira BioSciences, Inc. (PCRX). Click either name above to swap in a different company.
Pacira BioSciences, Inc. is the larger business by last-quarter revenue ($177.4M vs $167.7M, roughly 1.1× James River Group Holdings, Inc.). James River Group Holdings, Inc. runs the higher net margin — 19.1% vs 1.6%, a 17.5% gap on every dollar of revenue. On growth, James River Group Holdings, Inc. posted the faster year-over-year revenue change (32.4% vs 5.0%). Over the past eight quarters, Pacira BioSciences, Inc.'s revenue compounded faster (-0.2% CAGR vs -8.7%).
James River Corporation was an American pulp and paper company based in Richmond, Virginia, once the largest paper manufacturer in the world.
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
JRVR vs PCRX — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $167.7M | $177.4M |
| Net Profit | $32.1M | $2.9M |
| Gross Margin | — | — |
| Operating Margin | 14.6% | 3.9% |
| Net Margin | 19.1% | 1.6% |
| Revenue YoY | 32.4% | 5.0% |
| Net Profit YoY | 149.5% | — |
| EPS (diluted) | $0.59 | $0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $177.4M | ||
| Q4 25 | $167.7M | $196.9M | ||
| Q3 25 | $172.7M | $179.5M | ||
| Q2 25 | $174.8M | $181.1M | ||
| Q1 25 | $172.3M | $168.9M | ||
| Q4 24 | $126.7M | $187.3M | ||
| Q3 24 | $191.5M | $168.6M | ||
| Q2 24 | $188.3M | $178.0M |
| Q1 26 | — | $2.9M | ||
| Q4 25 | $32.1M | — | ||
| Q3 25 | $1.0M | $5.4M | ||
| Q2 25 | $4.8M | $-4.8M | ||
| Q1 25 | $9.6M | $4.8M | ||
| Q4 24 | $-64.8M | — | ||
| Q3 24 | $-39.4M | $-143.5M | ||
| Q2 24 | $7.6M | $18.9M |
| Q1 26 | — | — | ||
| Q4 25 | — | 79.5% | ||
| Q3 25 | — | 80.9% | ||
| Q2 25 | — | 77.4% | ||
| Q1 25 | — | 79.7% | ||
| Q4 24 | — | 78.7% | ||
| Q3 24 | — | 76.9% | ||
| Q2 24 | — | 75.1% |
| Q1 26 | — | 3.9% | ||
| Q4 25 | 14.6% | 1.2% | ||
| Q3 25 | 1.5% | 3.5% | ||
| Q2 25 | 4.2% | 4.7% | ||
| Q1 25 | 9.3% | 1.2% | ||
| Q4 24 | -57.0% | 13.2% | ||
| Q3 24 | -27.1% | -82.8% | ||
| Q2 24 | 10.7% | 15.9% |
| Q1 26 | — | 1.6% | ||
| Q4 25 | 19.1% | — | ||
| Q3 25 | 0.6% | 3.0% | ||
| Q2 25 | 2.7% | -2.7% | ||
| Q1 25 | 5.6% | 2.8% | ||
| Q4 24 | -51.1% | — | ||
| Q3 24 | -20.6% | -85.1% | ||
| Q2 24 | 4.0% | 10.6% |
| Q1 26 | — | $0.07 | ||
| Q4 25 | $0.59 | $0.05 | ||
| Q3 25 | $-0.02 | $0.12 | ||
| Q2 25 | $0.06 | $-0.11 | ||
| Q1 25 | $0.16 | $0.10 | ||
| Q4 24 | $-2.44 | $0.38 | ||
| Q3 24 | $-1.10 | $-3.11 | ||
| Q2 24 | $0.13 | $0.39 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $260.9M | $144.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $538.2M | $653.9M |
| Total Assets | $4.9B | $1.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $144.3M | ||
| Q4 25 | $260.9M | $238.4M | ||
| Q3 25 | $238.8M | $246.3M | ||
| Q2 25 | $220.0M | $445.9M | ||
| Q1 25 | $279.4M | $493.6M | ||
| Q4 24 | $362.3M | $484.6M | ||
| Q3 24 | $359.8M | $453.8M | ||
| Q2 24 | $672.5M | $404.2M |
| Q1 26 | — | — | ||
| Q4 25 | — | $372.2M | ||
| Q3 25 | — | $376.7M | ||
| Q2 25 | — | $580.5M | ||
| Q1 25 | — | $583.4M | ||
| Q4 24 | — | $585.3M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | $653.9M | ||
| Q4 25 | $538.2M | $693.1M | ||
| Q3 25 | $503.6M | $727.2M | ||
| Q2 25 | $492.6M | $757.8M | ||
| Q1 25 | $484.5M | $798.5M | ||
| Q4 24 | $460.9M | $778.3M | ||
| Q3 24 | $530.3M | $749.6M | ||
| Q2 24 | $541.8M | $879.3M |
| Q1 26 | — | $1.2B | ||
| Q4 25 | $4.9B | $1.3B | ||
| Q3 25 | $5.0B | $1.3B | ||
| Q2 25 | $5.0B | $1.5B | ||
| Q1 25 | $4.9B | $1.6B | ||
| Q4 24 | $5.0B | $1.6B | ||
| Q3 24 | $5.0B | $1.5B | ||
| Q2 24 | $4.7B | $1.6B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.54× | ||
| Q3 25 | — | 0.52× | ||
| Q2 25 | — | 0.77× | ||
| Q1 25 | — | 0.73× | ||
| Q4 24 | — | 0.75× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-18.8M | — |
| Free Cash FlowOCF − Capex | $-23.6M | — |
| FCF MarginFCF / Revenue | -14.1% | — |
| Capex IntensityCapex / Revenue | 2.9% | — |
| Cash ConversionOCF / Net Profit | -0.59× | — |
| TTM Free Cash FlowTrailing 4 quarters | $-17.9M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-18.8M | $43.7M | ||
| Q3 25 | $34.3M | $60.8M | ||
| Q2 25 | $25.2M | $12.0M | ||
| Q1 25 | $-51.5M | $35.5M | ||
| Q4 24 | $-247.1M | $33.1M | ||
| Q3 24 | $-269.9M | $53.9M | ||
| Q2 24 | $-8.7M | $53.2M |
| Q1 26 | — | — | ||
| Q4 25 | $-23.6M | $43.5M | ||
| Q3 25 | $33.7M | $57.0M | ||
| Q2 25 | $24.7M | $9.3M | ||
| Q1 25 | $-52.7M | $26.9M | ||
| Q4 24 | $-252.0M | $31.0M | ||
| Q3 24 | $-270.8M | $49.8M | ||
| Q2 24 | $-9.3M | $51.6M |
| Q1 26 | — | — | ||
| Q4 25 | -14.1% | 22.1% | ||
| Q3 25 | 19.5% | 31.7% | ||
| Q2 25 | 14.1% | 5.1% | ||
| Q1 25 | -30.6% | 15.9% | ||
| Q4 24 | -198.9% | 16.6% | ||
| Q3 24 | -141.4% | 29.6% | ||
| Q2 24 | -4.9% | 29.0% |
| Q1 26 | — | — | ||
| Q4 25 | 2.9% | 0.1% | ||
| Q3 25 | 0.4% | 2.2% | ||
| Q2 25 | 0.3% | 1.5% | ||
| Q1 25 | 0.7% | 5.1% | ||
| Q4 24 | 3.9% | 1.1% | ||
| Q3 24 | 0.4% | 2.4% | ||
| Q2 24 | 0.3% | 0.9% |
| Q1 26 | — | — | ||
| Q4 25 | -0.59× | — | ||
| Q3 25 | 33.61× | 11.20× | ||
| Q2 25 | 5.29× | — | ||
| Q1 25 | -5.38× | 7.37× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -1.14× | 2.82× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
JRVR
| Excess And Surplus Lines | $156.7M | 93% |
| Specialty Admitted Insurance | $10.9M | 7% |
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
